HIV/AIDS Topics CROI 2017: Treatment-as-Prevention Study Sees Substantial Drug Resistance, but No Impact on HIV Therapy
- Details
- Category: HIV Treatment
- Published on Tuesday, 28 February 2017 00:00
- Written by Gus Cairns
A study of the prevalence of transmitted drug resistance among participants in the ANRS 12249 trial of treatment as prevention, has found that a substantial minority of participants had HIV with drug resistance mutations. However, there was no evidence that pre-existing drug resistance had any impact on the success of treatment, according to a report at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
CROI 2017: New HIV Capsid Inhibitors Show High Potency and Prolonged Activity in Early Studies
- Details
- Category: Experimental HIV Drugs
- Published on Monday, 27 February 2017 00:00
- Written by Liz Highleyman
A novel type of antiretroviral drug that interferes with the assembly and disassembly of the HIV capsid, which encloses the genetic blueprint of the virus, may offer a new potent and long-acting treatment option if it continues to look promising in larger studies, according to a presentation at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.
CROI 2017: Spanish HIV Vaccine Induces Control Off ART in Nearly 40% of Recipients
- Details
- Category: Search for a Cure
- Published on Monday, 20 February 2017 00:00
- Written by Gus Cairns
A so-called "HIV Conserv" vaccine has, for the first time, produced significant prolonged viral control in a large minority of recipients once they were taken off antiretroviral therapy (ART). So far, 1 participant has stayed off ART for 7 months without having to resume it, according to a report at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.
CROI 2017: Monoclonal Antibodies Show Promise for HIV+ People with Few Treatment Options
- Details
- Category: Experimental HIV Drugs
- Published on Tuesday, 21 February 2017 00:00
- Written by Liz Highleyman
A pair of long-acting monoclonal antibodies that prevent HIV from entering human cells -- ibalizumab and PRO 140 -- may offer new treatment options for people with highly resistant virus and limited treatment options, researchers reported at the Conference on Retroviruses and Opportunistic Infections (CROI) last week in Seattle.
CROI 2017: Changes In Viral Suppression Over Time Reveal Disparities in HIV Care
- Details
- Category: HIV Treatment
- Published on Wednesday, 15 February 2017 00:00
- Written by Liz Highleyman
Sustained viral suppression over the course of a year may be a better measure than the most recent viral load test result when it comes to understanding access to and engagement in HIV care, according a study by Centers for Disease Control and Prevention (CDC) researchers presented at the 2017 Conference on Retroviruses and Opportunistic Infections this week in Seattle.
CROI 2017: New NNRTI Doravirine Shows Good Efficacy in Phase 3 Study
- Details
- Category: HIV Treatment
- Published on Monday, 20 February 2017 00:00
- Written by Liz Highleyman
Doravirine, an investigational next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) from Merck, reduced HIV viral load as well as boosted darunavir in a Phase 3 clinical trial of people starting antiretroviral therapy (ART) for the first time, but it had a better lipid profile, according to a late-breaking presentation at the Conference on Retroviruses and Opportunistic Infections last week in Seattle.
CROI 2017: New HIV Infections Fall in the U.S. but Disparities Remain
- Details
- Category: HIV Treatment
- Published on Wednesday, 15 February 2017 00:00
- Written by HIVandHepatitis.com
The number of annual new HIV infections in the U.S. fell by 18% overall since 2008, offering evidence that prevention and treatment efforts are having an impact, according to data from the Centers for Disease Control and Prevention (CDC) released to coincidence with presentations at the 2017 Conference on Retroviruses and Opportunistic Infections this week in Seattle. A closer look at the data, however, shows some notable differences across demographic groups and geographic regions.
More Articles...
- CROI 2017: Integrase Inhibitor Bictegravir Matches Dolutegravir for First-Line HIV Treatment
- CROI 2017: Dual Antiretroviral Regimen Maintains Durable HIV Suppression after Switch
- HIVandHepatitis.com 2016 Conference Coverage
- Top 10 HIV and Hepatitis Stories of 2016
- Dolutegravir + Rilpivirine HIV Maintenance Regimen Looks Good in Phase 3 Studies
Web Design and Development by